natgillin/translations-raw huggingface dataset:
Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. 
Uporaba imunoglobulina lahko za najmanj 6 tednov pa vse do 3 mesecev zmanjša učinkovitost cepiv z živim oslabljenim virusom, kot so cepiva proti ošpicam, rdečkam, mumpsu in noricam.
Treatment of adults, children and adolescents (2 - 18 years) who do not have sufficient antibodies (Flebogamma DIF is used as replacement therapy). 
Zdravljenje odraslih, otrok in mladostnikov (2-18 let), ki nimajo zadostnih protiteles (zdravilo Flebogamma DIF se uporablja kot nadomestno zdravljenje).
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo zdravila posvetujte z zdravnikom.
The dose that you will be given will depend on your illness and body weight and will be worked out by your doctor (please see section “Instructions for healthcare professionals” given at the end of this leaflet). 
Količino odmerka bo izračunal vaš zdravnik (glejte poglavje »Navodila za zdravstveno osebje« na koncu teh navodil za uporabo).
For intravenous use 
za intravensko uporabo
However, depending on the required dose, the patient may receive more than 1 vial. 
Vendar lahko bolnik prejme več kot 1 vialo, kar je odvisno od potrebnega odmerka.
Flebogamma DIF contains human normal immunoglobulin, highly purified protein extracted from human plasma (part of the blood of donors). 
Zdravilo Flebogamma DIF vsebuje humani polispecifični imunoglobulin, visoko prečiščeno beljakovino, pridobljeno iz človeške plazme (dela krvi krvodajalcev).
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). 
Spodnja preglednica temelji na podatkovni bazi MedDRA glede na organske sisteme (SOC in raven priporočenih izrazov).
After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. 
Po uporabi tega zdravila morajo preteči 3 meseci, preden bolnika cepite z živim oslabljenim virusnim cepivom.
However one subject treated with Flebogamma DIF 100 mg/ml presented mild episodes of headache in all infusions and one more patient had 2 episodes of pyrexia in 2 infusions. 
So se pa pri enem bolniku, zdravljenem z zdravilom Flebogamma DIF 100 mg/ml, pojavile epizode blagega glavobola pri vseh infuzijah, drug bolnik pa je imel 2 epizodi zvišane telesne temperature pri 2 infuzijah.
This medicine contains less than 29,41 mg sodium (main component of cooking/table salt) in each vial of 400 ml. 
To zdravilo vsebuje manj kot 29,41 mg natrija (glavne sestavine kuhinjske soli) na vialo s 400 ml.
There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to viral safety. 
Obstajajo pomirjujoče klinične izkušnje, ki kažejo, da se hepatitis A in parvovirus B19 ne prenašata z imunoglobulini, prav tako domnevajo, da vsebnost protiteles v veliki meri prispeva k varnosti pred virusi.
LIST OF EXCIPIENTS D-sorbitol, water for injections. 
SEZNAM POMOŽNIH SNOVI D-sorbitol, voda za injekcije.
Very common (may affect more than 1 in 10 infusions): ● headache 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 infuzij): ● glavobol.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. 
Prenosljivi povzročitelji bolezni Standardni ukrepi za preprečevanje okužb zaradi uporabe zdravil, ki so bila pripravljena iz človeške krvi ali plazme so med drugim izbor darovalcev, presejanje posameznih enot darovane krvi in združene plazme na specifične označevalce okužbe in vključitev učinkovitih postopkov za inaktivacijo/odstranitev virusov.
• (rarely) a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration 
• (redko) nenaden padec krvnega tlaka in v osamljenih primerih anafilaktični šok, tudi v primerih, ko bolnik ni kazal preobčutljivosti na predhodno dajanje zdravila,
It may happen particularly if you do not have enough immunoglobulins of the type IgA in your blood or have developed antibodies to IgA. 
Lahko se pojavijo zlasti, če nimate dovolj imunoglobulinov vrste IgA v krvi ali imate protitelesa proti imunoglobulinom IgA.
Anaphylaxis can develop in patients - with undetectable IgA who have anti-IgA antibodies - who had tolerated previous treatment with human normal immunoglobulin 
Anafilaksija se lahko razvije pri bolnikih: - z nezaznavnim IgA, ki imajo protitelesa proti IgA, - ki so prenašali predhodno zdravljenje s humanim normalnim imunoglobulinom.
In case of rubella, mumps and varicella a period of up to 3 months should elapse after receiving this medicine and before receiving these vaccines. 
V primeru cepiv proti rdečkam, mumpsu in noricam morajo po prejemanju tega zdravila preteči vsaj 3 meseci pred cepljenjem.
• productive cough 
• produktiven kašelj,
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. Do not store above 30 ºC. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in ovojnini poleg oznake EXP.
If you have a blood test after receiving Flebogamma DIF, please tell the analyst or your doctor that you have been given this medicine. 
Če imate po prejemu zdravila Flebogamma DIF preiskave krvi, obvestite osebo, ki kri analizira ali svojega zdravnika, da ste prejeli omenjeno zdravilo.
Interference with serological testing 
Vpliv na serološke preiskave
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products, nor with any other IVIg products. 
Zaradi pomanjkanja študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili, vključno z drugimi i.v.
• cases of reversible aseptic meningitis 
• primere reverzibilnega aseptičnega meningitisa,
The dose recommendations are summarised in the following table: 
Priporočljivi odmerki so povzeti v naslednji razpredelnici:
E-08150 Parets del Vallès Barcelona, Spain 
E-08150 Parets del Vallès Barcelona, Španija
Live attenuated virus vaccines 
(živih oslabljenih virusnih cepiv).
Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected. 
Klinične izkušnje z imunoglobulini ne kažejo škodljivih učinkov na potek nosečnosti ali plod ter novorojenca.
The dose required to achieve a trough level of IgG of 6 g/l is of the order of 0.2 - 0.8 g/kg/month. 
Odmerek, s katerim dosežete najnižjo raven IgG 6 g/l, je reda velikosti 0,2-0,8 g/kg/mesec.
● influenza like illness 
● bolezen, podobna gripi,
Polígono Levante Can Guasc, 2, E-08150 Parets del Vallès Barcelona, Spain 
Polígono Levante Can Guasc, 2, E-08150 Parets del Vallès Barcelona, Španija
Cerebrospinal fluid studies are frequently positive with pleocytosis up to several thousand cells per mm3, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl. AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment. 
Študije likvorja so pogosto pozitivne s pleocitozo do več tisoč celic na mm3, zlasti iz granulocitne linije, in zvišanimi ravnmi beljakovin do več sto mg/dl. AMS se lahko pojavi pogosteje v povezavi z velikimi odmerki
In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or age over 65. 
V večini primerov so ugotovili dejavnike tveganja, kot so obstoječa ledvična insuficienca, sladkorna bolezen, hipovolemija, čezmerna telesna masa, sočasno zdravljenje z nefrotoksičnimi zdravili ali starost nad
• Patients with Primary Immunodeficiency Syndromes (PID), an inborn lack of antibodies (group 1) 
• Bolniki s primarnimi sindromi imunske pomanjkljivosti, prirojenim pomanjkanjem protiteles (skupina 1),
• cases of increased serum creatinine level and/or occurrence of acute renal failure 
• primere zvišane ravni kreatinina v serumu in/ali akutne odpovedi ledvic,
2 g/kg in one dose in association with acetylsalicylic acid 
Kawasakijev sindrom2 g/kg v enem odmerku, ob sočasnem zdravljenju z acetilsalicilno kislino
Increase in the frequency of adverse reactions through the clinical trials likely related to the increased infusion rate has been observed (see section 4.2). 
V kliničnih preskušanjih so opazili povečanje pogostnosti neželenih učinkov, ki je verjetno povezano s povečano hitrostjo infundiranja (glejte poglavje 4.2).
• Increase in serum creatinine level (a test which measures your kidney function) and/or acute renal failure (which signs are low back pain, fatigue, decrease in the amount of urine). 
• Zvišanje ravni kreatinina v serumu (test, s katerim se izmeri delovanje ledvic) in/ali akutna odpoved ledvic (znaki so lahko bolečine v križu, utrujenost, zmanjšana količina urina).
The safety results for 4 paediatric patients (those ≤ 17 years old) included in the PID study and the results for the 13 children (aged 3 to 16 years old) included in the ITP study were evaluated. 
Ovrednotili so rezultate varnosti pri 4 pediatričnih bolnikih (starih ≤ 17 let), ki so sodelovali v študiji PID, in rezultate pri 13 otrocih (starih od 3 do 16 let), ki so sodelovali v študiji ITP.
Side effects may be reduced by switching to Flebogamma DIF 50 mg/ml. 
Neželene učinke je možno zmanjšati s prehodom na zdravilo Flebogamma DIF 50 mg/ml.
In persons more than 2 years old with HFI, a spontaneous aversion for fructose-containing foods develops and may be combined with the onset of symptoms (vomiting, gastro-intestinal disorders, apathy, height and weight retardation). 
Pri osebah s HFI, starejših od 2 let, se razvije spontana averzija za hrano, ki vsebuje fruktozo, lahko tudi v kombinaciji z nastankom simptomov (bruhanje, prebavne motnje, apatija, zaostajanje v višini in telesni masi).
The ability to drive and operate machines may be impaired by some adverse reactions, such as dizziness, associated with Flebogamma DIF. 
Na sposobnost vožnje in upravljanja strojev lahko vplivajo neželeni učinki, povezani z zdravilom Flebogamma DIF, kot je omotica.
• Cases of temporary non-infective meningitis (which signs are headache, fear or intolerance of light, stiff neck). 
• Primeri prehodnega neinfekcijskega meningitisa (znaki so lahko glavobol, strah pred svetlobo ali neprenašanje svetlobe, otrpel tilnik).
0.4 g/kg/day over 5 days (possible repeat of dosing in case of relapse). 
0,4 g/kg/dan v obdobju 5 dni (odmerjanje lahko ponovite, če pride do ponovitve bolezni).
It is strongly recommended that every time you receive a dose of Flebogamma DIF, the name and batch number of the medicine (stated on the label and carton after Lot) are recorded in order to maintain a record of the batches used. 
Zelo priporočljivo je, da vsakič, ko prejmete odmerek zdravila Flebogamma DIF, zabeležite ime in serijsko številko zdravila (navedena na nalepki in škatli poleg oznake Lot), da tako vodite evidenco o uporabljenih serijah zdravila.
Treatment of adults, children and adolescents (2 - 18 years) with certain autoimmune disorders (immunomodulation). 
Zdravljenje odraslih, otrok in mladostnikov (2-18 let) z nekaterimi avtoimunskimi motnjami (imunomodulacija).
• Primary immune thrombocytopenia (ITP), a condition where the number of platelets in the blood stream is greatly reduced. 
• Primarna imunska trombocitopenija (ITP), pri kateri je število trombocitov v krvi močno zmanjšano.
Frequency of injections 
Pogostnost injiciranja
Secondary immunodeficiencies 
Sekundarne imunske pomanjkljivosti
• blood volume decrease 
• zmanjšan volumen krvi
INFORMATION IN BRAILLE Justification for not including Braille accepted 
PISAVA V BRAILLOVI PISAVI Sprejeta je utemeljitev, da Braillova pisava ni potrebna
Hypersensitivity reactions are rare. 
Preobčutljivostne reakcije so redke.
In babies and young children (aged 0 - 2 years) hereditary fructose intolerance (HFI) may not yet be diagnosed and may be fatal, thus, they must not receive this medicinal product. 
Pri dojenčkih in majhnih otrocih (starih od 0-2 leti) morda še ni bila postavljena diagnoza dedne intolerance za fruktozo (HFI - hereditary fructose intolerance), ki je lahko smrtna, zato ne smejo prejemati tega zdravila.
Multifocal motor neuropathy (MMN) 
Multifokalna motorična nevropatija (MMN)
• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a rare and progressive disease causing limb weakness, numbness, pain and fatigue. 
• Kronična vnetna demielinizacijska poliradikulonevropatija (CIDP), redka in napredujoča bolezen, ki povzroča oslabelost okončin, otopelost, bolečine in utrujenost.
Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. 
Kljub tem ukrepom pri uporabi zdravil, ki so pripravljena iz človeške krvi ali plazme, ni mogoče popolnoma izključiti možnosti prenosa okužbe.
• history of vascular disease or thrombosis 
• žilna obolenja ali trombozo
• Patients with Secondary Immunodeficiency Syndromes (SID) with severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l (group 2) 
• Bolniki s sekundarnimi sindromi imunske pomanjkljivosti (SID) z resnimi ali ponavljajočimi se okužbami, neučinkovitim protimikrobnim zdravljenjem ter potrjenim neuspehom specifičnega protitelesa (PSAF)* ali serumsko ravnjo IgG <4 g/l (skupina 2).
Information on overdose in children has not been established with Flebogamma DIF. 
Informacij o prevelikem odmerjanju zdravila Flebogamma DIF pri otrocih ni.
The dose in children is not considered to be different to that of adults as it will be given depending on the illness and body weight of the children. 
Odmerjanje pri otrocih se ne razlikuje od odmerjanja pri odraslih, saj bo zdravilo dano v odmerku, ki je odvisen od bolezni in telesne mase otroka.
• 0.8 - 1 g/kg given on day one; this dose may be repeated once within 3 days. 
• odmerek 0,8-1 g/kg prvi dan; ta odmerek lahko ponovite enkrat v roku 3 dni,
● bronchitis 
● bronhitis,
- If you do not have enough immunoglobulins of the type IgA in your blood or have developed antibodies to IgA. 
- Če nimate dovolj imunoglobulinov vrste IgA v krvi ali imate protitelesa proti imunoglobulinom IgA.
Replacement therapy: Primary immunodeficiency syndromes 
Nadomestno zdravljenje: Sindromi primarne imunske pomanjkljivosti
To hang pull here 
Da obesite, povlecite tukaj.
Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgA-containing product can result in anaphylaxis. 
Bolniki s selektivno pomanjkljivostjo IgA, ki so razvili protitelesa proti IgA, saj lahko dajanje zdravila, ki vsebuje IgA, povzroči anafilaksijo.
• alanine aminotransferase (hepatic transaminase) increased 
• zvišana alanin aminotransferaza (jetrna transaminaza),
Do not store above 30 ºC. 
Shranjujte pri temperaturi do 30 ºC.
This medicinal product contains less than 29,41 mg sodium per vial of 400 ml, equivalent to 1.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
To zdravilo vsebuje manj kot 29,41 mg natrija na vialo s 400 ml, kar je enako 1,5 % največjega dnevnega vnosa natrija za odrasle osebe, ki ga priporoča SZO in znaša 2 g.
Platelets form an important part of the clotting process and a reduction in their numbers may cause unwanted bleeding and bruising. 
Trombociti so pomembni za strjevanje krvi, zmanjšanje števila trombocitov pa lahko povzroči neželeno krvavitev in modrice.
Flebogamma DIF should not be mixed with other medicines or intravenous solutions and it should be administered by a separate intravenous line. 
Zdravila Flebogamma DIF ne smete mešati z drugimi zdravili ali intravenskimi raztopinami, uporabiti se mora z ločeno intravensko cevko.
Source of the safety database from clinical trials and post-authorisation safety studies in a total of 160 patients exposed to Flebogamma DIF 100 mg/ml (with a total of 915 infusions) 
Vir zbirke podatkov o varnosti iz kliničnih preskušanj in študij varnosti po pridobitvi dovoljenja za promet pri skupno 160 bolnikih, izpostavljenih zdravilu Flebogamma DIF 100 mg/ml (s skupno 915 infuzijami)
One ml contains 50 mg of D-sorbitol. 
En ml vsebuje 50 mg D-sorbitola.
In rare and isolated cases, the following side effects have been reported with immunoglobulin preparations. 
Pri pripravkih z imunoglobulini so pri redkih in posameznih primerih poročali o naslednjih neželenih učinkih.
TRALI is characterised by severe hypoxia, dyspnoea, tachypnoea, cyanosis, fever and hypotension. 
Za TRALI so značilne resna hipoksija, dispneja, tahipneja, cianoza, zvišana telesna temperatura in hipotenzija.
The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects. 
Mehanizem delovanja pri indikacijah, ki niso del nadomestnega zdravljenja, ni v celoti pojasnjen,
The product is also used in patients at high risk of bleeding or prior to surgery to correct the platelet count. 
To zdravilo se uporablja tudi pri bolnikih z velikim tveganjem krvavitve ali pred kirurškimi posegi za povečanje števila trombocitov.
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous use 
POSTOPEK IN POT(I) UPORABE ZDRAVILA za intravensko uporabo
● radicular syndrome (neck or back pain and other symptoms such as numbness, tingling and weakness in the arms or legs) 
● nespečnost, ● radikularni sindrom (bolečine v vratu in hrbtu in drugi simptomi, kot so otopelost, mravljinčenje ter šibkost rok in nog),
Can Guasc, 2 - Parets del Vallès 08150 Barcelona - Spain 
Can Guasc, 2 - Parets del Vallès 08150 Barcelona - Španija
Source of the safety database from clinical trials and post-authorisation safety studies in a total of 128 patients exposed to Flebogamma DIF 50 mg/ml (with a total of 1318 infusions) 
Vir zbirke podatkov o varnosti iz kliničnih preskušanj in študij varnosti po pridobitvi dovoljenja za promet pri skupno 128 bolnikih, izpostavljenih zdravilu Flebogamma DIF 50 mg/ml (s skupno 1318 infuzijami)
Dose based on body weight may require adjustment in underweight or overweight patients. 
Odmerek na osnovi telesne mase bo morda treba prilagoditi pri bolnikih s premajhno ali preveliko telesno maso.
It has a distribution of immunoglobulin G subclasses closely proportional to that in native human plasma. 
Porazdelitev podrazredov imunoglobulina G je izjemno podobna tisti pri naravni človeški plazmi.
After receiving Flebogamma DIF, the results of certain blood tests (serological tests) may be interfered for a certain time. 
Po uporabi zdravila Flebogamma DIF so lahko rezultati nekaterih krvnih preiskav (seroloških testov)
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.5 g / 10 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 0,5 g / 10 ml
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Instituto Grifols, S.A. 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Instituto Grifols, S.A.
Therefore patients receiving measles vaccine should have their antibody status checked. 
Zato se mora pri bolnikih, ki bodo prejeli cepivo proti ošpicam, preveriti prisotnost protiteles.
Do not use this medicine if you notice that the solution is cloudy or has deposits. 
Tega zdravila ne uporabljajte, če opazite, da je raztopina motna ali da je v njej oborina.
• Thromboembolic reactions such as myocardial infarction (tight band around the chest with feeling like your heart is beating too fast), stroke (muscle weakness in the face, arm, or leg, trouble speaking or understanding others who are speaking), pulmonary embolism (shortness of breath, chest pain and fatigue), deep vein thromboses (pain and swelling in an extremity). 
• Trombembolični dogodki, kot so miokardni infarkt (občutek stiskanja okoli prsi in prehitrega utripanja srca), možganska kap (šibkost mišic obraza, rok ali nog, težave z govorjenjem ali razumevanjem govorice drugih), pljučna embolija (kratka sapa, bolečine v prsih in utrujenost)
• (very rarely) thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses 
• (zelo redko) trombembolične dogodke, kot so miokardni infarkt, možganska kap, pljučna embolija in globoke venske tromboze,
While reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products containing various excipients such as sucrose, glucose and maltose, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number. 
Ig z dovoljenjem za promet, ki vsebujejo različne pomožne snovi, kot so saharoza, glukoza in maltoza, so zdravila s saharozo kot stabilizatorjem odgovorna za nesorazmerno velik delež celotnega števila poročil.
You must make up the infusion in exactly the way you have been shown in order to stop germs getting in. You must never self-administer it alone; a responsible adult must be always present. 
Nikoli ne opravljajte infuzije sami, zmeraj mora pri infundiranju biti prisotna odgovorna odrasla oseba.
• diseases which increase blood viscosity • age over 65 
• bolezni, ki povečujejo viskoznost krvi
• infusion site reactions (erythema, extravasation, inflammation, pain) 
• reakcije na mestu infundiranja (eritem, ekstravazacija, vnetje, bolečina),
SPECIAL STORAGE CONDITIONS Do not store above 30 ºC. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30 °C.
In case of inadvertent administration and suspicion of fructose intolerance the infusion has to be stopped immediately, normal glycaemia has to be re-established and organ function has to be stabilized by means of intensive care. 
Če se zdravilo uporabi nenamerno in obstaja sum na intoleranco za fruktozo, je treba infundiranje takoj prekiniti, doseči normalno glikemijo in z intenzivno nego stabilizirati delovanje organov.
What Flebogamma DIF is and what it is used for What you need to know before you use Flebogamma DIF How to use Flebogamma DIF Possible side effects 
Kaj je zdravilo Flebogamma DIF in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Flebogamma DIF Kako uporabljati zdravilo Flebogamma DIF
Post-authorisation Safety Study 
Študija o varnosti zdravila po pridobitvi dovoljenja za promet
If you have a renal disease and you are receiving Flebogamma DIF for the first time, you may suffer a problem in your kidneys. 
Bolniki z ledvičnimi težavami Če imate bolezen ledvic in prejemate zdravilo Flebogamma DIF prvič, lahko pride do ledvičnih težav.
OTHER To hang pull here 
DRUGI PODATKI Da obesite, povlecite tukaj.
In patients receiving IVIg, there have been some reports of acute non-cardiogenic pulmonary oedema [Transfusion Related Acute Lung Injury (TRALI)]. 
Ig, so poročali o nekaj primerih akutnega nekardiogenega pljučnega edema [s transfuzijo povezane akutne poškodbe pljuč (TRALI - Transfusion Related Acute Lung Injury)].
Human normal immunoglobulin is immediately and completely bioavailable in the recipient's circulation after intravenous administration. 
Humani polispecifični imunoglobulin je po intravenski uporabi takoj in v celoti biološko uporaben v krvnem obtoku prejemnika.
If the treatment is effective long term treatment should be subject to the physicians discretion based upon the patient response and maintenance response. 
Če je zdravljenje učinkovito, mora zdravnik na osnovi bolnikovega odziva in vzdrževanja odziva presoditi, ali je primerno dolgotrajno zdravljenje.